More articles from Volume 48, Issue 1, 2019
Clinical-morphological characteristics of pathological changes in the prostate
Serum Vitamin D analysis in acute viral bronchiolitis
Extracranial carotid atherosclerosis in genesis infarction brain in the border zones supratentorial localization
Oxidative stress parameters in patients with Meniere disease
The impact of occupational stress on work ability of electricians
Clinical-morphological characteristics of pathological changes in the prostate
,
Aleksandra Ilić
Dejan Denović
Abstract
References
1.
Abrahamsson PA, Falkmer S, Fält K, Grimelius L. The course of neuroendocrine differentiation in prostatic carcinomas. Vol. 185, Pathology - Research and Practice. 1989. p. 373–80.
2.
Baisden BL, Kahane H, Epstein JI. Perineural Invasion, Mucinous Fibroplasia, and Glomerulations. Vol. 23, The American Journal of Surgical Pathology. 1999. p. 918.
3.
Beahrs OH, Henson DE, Hutter RP, Kennedy BJ. American Joint Committee on Cancer staging manual for staging of cancer. 1992.
4.
Bostwick DG, Amin MB, Dundore P, Marsh W, Schultz DS. Architectural patterns of high-grade prostatic intraepithelial neoplasia. Vol. 24, Human Pathology. 1993. p. 298–310.
5.
Bostwick DG, Grignon DJ, Hammond MEH, Amin MB, Cohen M, Crawford D, et al. Prognostic Factors in Prostate Cancer. Vol. 124, Archives of Pathology & Laboratory Medicine. 2000. p. 995–1000.
6.
Bostwick DG, Qian J. High-grade prostatic intraepithelial neoplasia. Vol. 17, Modern Pathology. 2004. p. 360–79.
7.
Bumbaširević V, Lačković V, Milićević NM, Milićevic Ž, Mujović S, Obradović M, et al. Histologija Medicinski fakultet. 2005.
8.
Catalona WJ. Evaluation of Percentage of Free Serum Prostate-Specific Antigen to Improve Specificity of Prostate Cancer Screening. Vol. 274, JAMA: The Journal of the American Medical Association. 1995. p. 1214.
9.
Cook PJ, Doll R, Fellingham SA. A mathematical model for the age distribution of cancer in man. Vol. 4, International Journal of Cancer. 1969. p. 93–112.
10.
Edge S, Byrd DR, CC C. American Joint Committee on Cancer staging manual. 2010.
11.
JI E, WM M. Diseases of the prostate gland and seminal vesicels. In 1997. p. 148–241.
12.
Epstein JA, Jang. Prostate biopsy interpretation. 2002.
13.
I.P G, JL H. Color textbook of Histology. 2006.
14.
Ghani KR, Grigor K, Tulloch DN, Bollina PR, McNeill SA. Trends in Reporting Gleason Score 1991 to 2001: Changes in the Pathologist’s Practice. Vol. 47, European Urology. 2005. p. 196–201.
15.
Gleason DF. Histologic grading of prostate cancer: A perspective. Vol. 23, Human Pathology. 1992. p. 273–9.
16.
In 7AD.
17.
GREENE DR, WHEELER TM, EGAWA S, WEAVER RP, SCARDINO PT. Relationship between Clinical Stage and Histological Zone of Origin in Early Prostate Cancer: Morphometric Analysis. Vol. 68, British Journal of Urology. 1991. p. 499–509.
18.
Humphrey PA. Gleason grading and prognostic factors in carcinoma of the prostate. Vol. 17, Modern Pathology. 2004. p. 292–306.
19.
Institut za javno zdravlje Srbije “Dr Milan Jovanović Batut”: Incidencija i mortalitet od raka u Centralnoj Srbiji 2012, Registar za rak u Centralnoj Srbiji izveštaj br. 14. 2014.
20.
Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. Vol. 60, CA: A Cancer Journal for Clinicians. 2010. p. 277–300.
21.
Krušlin B, Tomas D, Rogatsch H, Novosel I, Čupić H, Belicza M, et al. Periacinar retraction clefting in the prostatic needle core biopsies: an important diagnostic criterion or a simple artifact? Vol. 443, Virchows Archiv. 2003. p. 524–7.
22.
Krušlin B, Tomas D, Čviko A, Čupić H, Odak L, Belicza M. Periacinar clefting and p63 immunostaining in prostatic intraepithelial neoplasia and prostatic carcinoma. Vol. 12, Pathology & Oncology Research. 2006. p. 205–9.
23.
McNeal JE, Price HM, Redwine EA, Freiha FS, Stamey TA. Stage A Versus Stage B Adenocarcinoma of the Prostate: Morphological Comparison and Biological Significance. Vol. 139, Journal of Urology. 1988. p. 61–5.
24.
McNeal JE, Redwine EA, Freiha FS, Stamey TA. Zonal Distribution of Prostatic Adenocarcinoma. Vol. 12, The American Journal of Surgical Pathology. 1988. p. 897–906.
25.
Mijović M, Vukićević D, Mitić N, Kneževic M, Đerković B. Periacinarne pukotine u adenokarcinomu prostate, prostaticnoj intraepitelnoj neoplaziji i benignoj hiperplaziji prostate. Vol. 38. 2010. p. 1–7.
26.
Mijovic M, Vukicevic D, Djerkovic B, Nedeljkovic V, Vitkovic L. Significance of periacinar cleftings as supporting criteria in diagnosis of prostatic adenocarcinoma Gleason score-a 7 (3+4) and Gleason score-a 7 (4+3) and their relationship with parameters of predictive value. Vol. 43, Praxis medica. 2014. p. 59–69.
27.
Mijovic M, Corac A, Smiljic S, Savic S, Mandic P, Vitkovic L, et al. Correlation of focal neuroendocrine differentiation in prostate cancer with the parameters of predictive value. Vol. 76, Vojnosanitetski pregled. 2019. p. 1115–26.
28.
Mijovic M, Vukicevic D, Djerkovic B, Nedeljkovic V, Vitkovic L. Prognostic significance of Gleason score 7 (3+4) and Gleason score 7 (4+3) in prostatic adenocarcinoma in relation to clinical stage, androgen tissue status and degree of neuroendocrine differentiation. Vol. 43, Praxis medica. 2014. p. 1–12.
29.
Mijovic M, Vukicevic D, Djerkovic B, Savic S, Vitkovic L, Nedeljkovic V. Specificity and sensitivity of preoperative total serum prostate specific antigen in diagnosis most common histopathological change of prostate. Vol. 46, Praxis medica. 2017. p. 9–19.
30.
Mijović M. Fokalna neuroendokrina diferencijacija adenokarcinoma prostate u korelaciji sa histološkim gradusom, kliničkim stadijumom i preoperativnim vrednostima serumskog prostata specifičnog antigena, doktorska disertacija. 2010.
31.
MOORE CK, KARIKEHALLI S, NAZEER T, FISHER HAG, KAUFMAN RP, MIAN BM. PROGNOSTIC SIGNIFICANCE OF HIGH GRADE PROSTATIC INTRAEPITHELIAL NEOPLASIA AND ATYPICAL SMALL ACINAR PROLIFERATION IN THE CONTEMPORARY ERA. Vol. 173, Journal of Urology. 2005. p. 70–2.
32.
GJ OD, RW V, M CM, SB S. The Gleason score: a significant biologic manifestation of prostate cancer agressiveness on biopsy. 2001.
33.
Parker C, Gillessen S, Heidenreich A, Horwich A. Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Vol. 26, Annals of Oncology. 2015. p. v69–77.
34.
Partin AW. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. Vol. 277, JAMA: The Journal of the American Medical Association. 1997. p. 1445–51.
35.
Popov I, Lj RJ. Prostate specific antigen (PSA) in the diagnosis and treatment of prostate carcinoma, advances and controversies. Vol. 129. 2001. p. 159–62.
36.
RAMOS CG, CARVAHAL GF, MAGER DE, HABERER B, CATALONA WJ. THE EFFECT OF HIGH GRADE PROSTATIC INTRAEPITHELIAL NEOPLASIA ON SERUM TOTAL AND PERCENTAGE OF FREE PROSTATE SPECIFIC ANTIGEN LEVELS. Vol. 162, Journal of Urology. 1999. p. 1587–90.
37.
Ronnett BM, Carmichael MJ, Carter HB, Epstein JI. Does High Grade Prostatic Intraepithelial Neoplasia Result in Elevated Serum Prostate Specific Antigen levels? Vol. 150, Journal of Urology. 1993. p. 386–9.
38.
Wael Sakr A, Billis A, Ekman P, Wilt T, Bostwick DG. Epidemiology of High-Grade Prostatic Intraepithelial Neoplasia. Vol. 34, Scandinavian Journal of Urology and Nephrology. 2000. p. 11–8.
39.
Stamatiou K, Alevizos A, Agapitos E, Sofras F. Incidence of impalpable carcinoma of the prostate and of non-malignant and precarcinomatous lesions in Greek male population: An autopsy study. Vol. 66, The Prostate. 2006. p. 1319–28.
Citation
Copyright
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Article metrics
Google scholar:
See link
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
